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Abstract
The objective of this study was to document pan-European real-world treatment patterns and healthcare resource use and estimate
opportunities for early switch (ES) from intravenous (IV) to oral antibiotics and early discharge (ED) in hospitalized patients with
methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infections (cSSTIs). This retrospective observational
medical chart review study enrolled 342 physicians across 12 European countries who collected data from 1542 patients with documented
MRSA cSSTI who were hospitalized (July 2010 to June 2011) and discharged alive (by July 2011). Data included clinical characteristics and
outcomes, hospital length of stay (LOS), MRSA-targeted IV and oral antibiotic use, and ES and ED eligibility according to literature-based and
expert-validated criteria. The most frequent initial MRSA-active antibiotics were vancomycin (50.2%), linezolid (15.1%), clindamycin (10.8%),
and teicoplanin (10.4%). Patients discharged with MRSA-active antibiotics (n = 480) were most frequently prescribed linezolid (42.1%) and
clindamycin (19.8%). IV treatment duration (9.3  6.5 vs. 14.6  9.9 days; p <0.001) and hospital LOS (19.1  12.9 vs. 21.0  18.2 days;
p 0.162) tended to be shorter for patients switched from IV to oral treatment than for patients who received IV treatment only. Of the
patients, 33.6% met ES criteria and could have discontinued IV treatment 6.0  5.5 days earlier, and 37.9% met ED criteria and could have
been discharged 6.2  8.2 days earlier. More than one-third of European patients hospitalized for MRSA cSSTI could be eligible for ES and
ED, resulting in substantial reductions in IV days and bed-days, with potential savings of €2000 per ED-eligible patient.
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Introduction
Hospitalization for complicated skin and soft tissue infections
(cSSTI) caused by methicillin-resistant Staphylococcus aureus
(MRSA) represents a substantial clinical and economic burden
[1,2]. The standard treatment option for MRSA cSSTI is the
administration of intravenous (IV) antibiotics (frequently
vancomycin), often involving hospitalization.
Decreasing hospital capacity (http://www.hope.be/03activ
ities/quality_eu-hospitals/eu_country_profiles/00-hospitals_in_
europe-synthesis_vs2011-06.pdf) and increasing economic
pressure underscore the importance of optimizing care. One
key antibiotic stewardship strategy with the potential to
improve efficiency is promoting IV-to-oral (PO) switch treat-
ment to facilitate hospital discharge while maintaining equiv-
alent outcomes [3]. PO antibiotic use can help to optimize
inpatient bed use, and IV-to-PO switch treatment is not a
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resource-intensive core stewardship strategy (it is implement-
able in resource-limited settings) [4].
European hospitals should observe and document current
practice to identify opportunities for early switch (ES) from IV
to PO antibiotic treatment, and early discharge (ED) from
inpatient to outpatient IV or PO antibiotic treatment, to
improve the delivery of effective and fiscally prudent manage-
ment of infections. Throughout Europe, inpatient IV vancomy-
cin therapy is used for MRSA cSSTI throughout treatment,
although PO antibiotic options are available. We therefore
conducted a pan-European real-world study of treatment
patterns, healthcare resource use and criteria-based assess-
ment of ES/ED opportunities in patients with MRSA cSSTI.
Methods
This retrospective observational medical chart review study
enrolled patients from 12 European countries (the UK, Ireland,
France, Germany, Italy, Spain, Portugal, Austria, Greece,
Poland, Slovakia, and the Czech Republic). An observational
study design was chosen to determine real-world treatment
patterns and resource use. Medical charts of hospitalized
patients with MRSA cSSTI (admitted from 1 July 2010 to 30
June 2011, and discharged alive by 31 July 2011) were
randomly sampled for data on clinical and resource utilization
outcomes. Patients prescribed IV-to-PO switch antibiotic
treatment for MRSA cSSTI were non-randomly oversampled
(after random sample quotas were achieved) to allow a
sufficient sample size to compare IV-only and IV-to-PO switch
MRSA-targeted treatment. The protocol did not specify which
antibiotics to select in the random sample or oversample, and
site investigators were blinded to the sponsor to minimize bias
in the selection of medical charts. Real-world treatment
patterns and outcomes were documented, and ES/ED eligibility
criteria (Table 1) were identified.
Patient inclusion and exclusion criteria
Patients were identified by hospital-based infectious disease
specialists, internal medicine specialists (with infectious disease
subspecialties), and medical microbiologists. Patients had a
new, microbiologically confirmed MRSA cSSTI (e.g. deep/
extensive cellulitis, infected wound or ulcer, major abscess, or
other soft tissue infections requiring substantial surgical
intervention) and received ≥3 days of IV anti-MRSA antibiotics.
Exclusion criteria included: treatment for the same cSSTI
within 3 months of hospitalization (to assess re-hospitaliza-
tions resulting from an initial cSSTI, without including recur-
rent infections); suspected/proven diabetic foot infections,
osteomyelitis, infective endocarditis, meningitis, joint infec-
tions, necrotizing soft tissue infections, gangrene, prosthetic
joint infection, or prosthetic implant/device infection; signifi-
cant concomitant infection at other sites; immunosuppression;
pregnancy/lactation in women; or enrolment in another
cSSTI-related clinical trial.
Study populations and subgroups
The primary study population included patients whose medical
charts were randomly selected for the purpose of describing
MRSA cSSTI patient characteristics, clinical management
patterns, and ES/ED eligibility across Europe.
Antibiotic treatment patterns were described for a con-
firmed MRSA-active treatment subgroup (labelled indication
for MRSA treatment or with confirmatory culture susceptibil-
ity). A second subgroup was compared for IV days and hospital
length of stay (LOS) between patients switched from IV to PO
treatment and those receiving IV-only treatment.
Key outcomes
The key study endpoints and ES/ED criteria utilized included
both IV-related and LOS-related outcomes (Table 1).
Actual LOS and medical treatment patterns were determined
from the primary study population. Time to MRSA-active
treatment, number of lines of MRSA-active treatment, length
of inpatient MRSA-active IV treatment, frequency of antibiotic
changes, first and last MRSA-active antibiotics used and fre-
quency of MRSA-targeted antibiotics at hospital discharge were
determined for the subgroup receiving MRSA-active treatment.
ES/ED eligibility criteria for use in real-world clinical settings
were created from literature review [5–13] and expert
consensus opinion (Table 1). Patients meeting ES/ED criteria
were identified within the primary study population. A
hypothetical length of IV treatment (days between the start
of initial MRSA-targeted IV treatment and the date when the
last key ES criterion was met) and hypothetical LOS (days
between hospital admission for cSSTI or the date on which
cSSTI was diagnosed and the date when the last ED criterion
was met) were then calculated (Table 1).
To determine the potential economic impact of ED,
bed-days saved for ED-eligible patients were multiplied by
unit costs of providing a hospital bed in the year 2008 (http://
www.who.int/choice/country/country_specific/en/index.html),
in international dollars, adjusted for inflation to 2012 and
converted to Euros (http://epp.eurostat.ec.europa.eu/tgm/
table.do?tab=table&language=en&pcode=tec00118&tableSe-
lection=1&footnotes=yes&labeling=labels&plugin=1). Costs
included the ‘hotel’ component of hospital costs, and not
drug/diagnostic test costs. To provide a cost reflective of the
patient distribution among the countries sampled, a cross-
country average was calculated (Appendix S1).
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Statistical analysis
Descriptive analyses were conducted for all study populations.
Within the MRSA-active treatment subgroup, patients were
stratified by antibiotic administration pattern (IV only or
IV-to-PO switch). For categorical or ordinal outcomes,
Pearson’s chi-square tests were used for bivariate statistical
testing. For continuous outcomes, Student’s t-tests and
one-way analysis of variance tests were used. All inferences
were made on the assumption of a two-sided test with
alpha = 0.05.
Results
The primary study population comprised 1502 patients
randomly selected by 342 physicians for chart abstraction.
The MRSA-active treatment subgroup included 1468 patients
who received at least one medication with confirmed
anti-MRSA activity. The subgroup for IV-only vs. IV-to-PO
switch comparisons included 1508 patients (1468 receiving
MRSA-active treatment plus 40 oversampled patients who
received MRSA-active IV-to-PO switch treatment).
Patient and clinical characteristics
Most patients were white males, with an average age at
hospital admission of 60.9 years (Table 2). The primary reason
for hospitalization was MRSA cSSTI (80.8%); the most
common infections were deep/extensive cellulitis (26.1%),
surgical site infections of post-traumatic wounds (26.0%), and
infected ulcers (24.7%). Of the patients, 38.7% required
surgical intervention for cSSTI management. Among the main
sample, 1475 (98.2%) patients had at least one cSSTI wound
TABLE 1. Definitions of study endpoints and early switch (ES)/early discharge (ED) criteria
IV-related endpoints
Actual length of IV usage Time between initiation of MRSA-targeted IV therapy and last day of MRSA-targeted IV therapy (for patients
switched from IV to PO) or discharge (IV-only patients)
ES eligibility At minimum, the following key criteria needed to be met prior to actual IV discontinuation:
 Stable clinical infection
 Afebrile/temperature of <38°C for 24 h
 WBC count normalizing, WBC count not <4 9 109/L or >12 9 109/L
 No unexplained tachycardia
 Systolic blood pressure of ≥100 mm Hg
 Patient tolerates PO fluids/diet and able to take PO medications with no gastrointestinal absorption problems
Additional criteria related to ES that were assessed, but not required to be documented, included:
 Available bacteriology for cSSTI caused by MRSA that is sensitive to PO treatment
 Available bacteriology for cSSTI caused by MRSA that is sensitive to OPAT
 No surgery scheduled within the next 36 h
 No requirement for IV line other than administration of IV antibiotic therapy
Hypothetical IV days Days between the day of initial MRSA-targeted IV antibiotic administration and the date when the patient satisfied
the last of the key ES criteria listed above
Potential reduction in IV days Difference in days between actual and hypothetical IV days among ES-eligible patients
LOS-related endpoints
LOS (from beginning of
cSSTI episode)
Number of days from cSSTI indexa and hospital discharge
ED eligibility At minimum, the following criteria needed to be met prior to discharge:
 All key ES eligibility criteria listed above
 No other reason to stay in hospital except infection management
Additional criteria related to ED that were assessed, but not required to be documented, included:
 Stable mental status
 Stable comorbid illnesses
 Stable social situation
Hypothetical LOS Number of days from cSSTI indexa to the date when the patient satisfied all key required criteria and actual LOS
Potential reduction in
LOS (bed-days saved)
Difference in days between actual and hypothetical LOS among ED-eligible patients
cSSTI, complicated skin and soft-tissue infection; IV, intravenous; LOS, length of stay; MRSA, methicillin-resistant Staphylococcus aureus; OPAT, outpatient parenteral antibiotic
therapy; PO, oral; WBC, white blood cell.
aDate of admission for patients admitted for cSSTI; cSSTI diagnosis date otherwise. In cases where the cSSTI diagnosis date was earlier than the admission date, the admission date
was used.
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culture performed; among these, susceptibility testing was
performed in 1319 (89.4%).
Most patients had one or more comorbidities at admission
(most commonly: diabetes, 31.3%; and peripheral vascular
disease, 23.8%). Many patients (17.2%) had sepsis. Patient
demographic and clinical characteristics of the main study
population were similar to those of the subgroups. However,
diabetes and cerebrovascular comorbidities and infected ulcer
and infected burn cSSTI diagnoses were more common in
patients with IV-only treatment than in those with IV-to-PO
switch treatment.
Actual treatment patterns and healthcare resource
utilization
Within the primary study population, 1224 patients (81.5%)
received only IV MRSA-active treatment; 161 (10.7%) were
switched from IV to PO MRSA-active treatment while
hospitalized; 83 (5.6%) had other MRSA-active treatment
patterns (e.g. concomitant use of PO and IV antibiotics
through discharge or switch from IV to PO to IV); and 34
(2.3%) received antibiotic treatment not confirmed to be
MRSA-active. The mean ( standard deviation (SD)) LOS
from cSSTI diagnosis to discharge was 20.6  17.4 days.
Other resource utilization included surgical procedures
(debridement/incision/drainage) in 38.7% of patients.
MRSA-active treatment subgroup. The mean (SD) time to
administration of MRSA-active treatment was 1.2  2.7 days
following MRSA cSSTI diagnosis. The mean (SD) length of
MRSA-active treatment by any route (i.e. IV, intramuscular, or
PO) was 14.8  9.9 days, and the mean length of MRSA-active
IV treatment was 14.0  9.7 days. One thousand one hun-
dred and eighty-nine patients (81.0%) were treated with a
single MRSA-active antibiotic regimen, 261 patients (17.8%)
changed at least one MRSA-active regimen and 18 patients
(1.2%) modified their antibiotic regimen twice while in the
hospital (changes from IV to PO formulations of the same
medication were not counted as a regimen change). Reasons
for the change of antibiotic or dosing were not always
documented in medical charts. The most common reason for
vancomycin dose change was drug-level maintenance (38.6%),
and those for teicoplanin dose change were protocol/guide-
lines (27.4%) and loading dose (19.2%). Among 161 (11.0%)
patients who switched to PO treatment during their hospital
stay, the most common reasons for switching included
improvement of symptoms (50.9%), convenience (5.6%), and
lack of drug resistance (5.6%).
The most frequently prescribed initial MRSA-active antibi-
otic was vancomycin, followed by linezolid, clindamycin, and
teicoplanin (Table 3). Analysis of final inpatient MRSA-active
antibiotic regimens showed that, during the course of treat-
ment, the proportion of inpatients receiving vancomycin
decreased, and the proportion of inpatients receiving linezolid
increased. In the MRSA-active treatment subgroup, 480
patients (32.7%) were discharged on either parenteral (7.3%)
or PO (92.7%) MRSA-active antibiotics. Linezolid was the most
frequently prescribed antibiotic (42.1%, with >98% receiving
PO linezolid) at discharge.
IV-to-PO switch MRSA-active oversampled subgroup. The duration
of IV therapy was significantly shorter and hospital LOS was
numerically shorter for patients switched from IV to PO
treatment (n = 197) than for patients receiving IV treatment
throughout (n = 1228). The mean (SD) duration of IV
treatment for patients switched from IV to PO treatment was
9.3  6.5 days, and that for patients receiving IV-only treat-
ment was 14.6  9.9 days (p <0.001). Mean (SD) hospital
LOS was 19.1  12.9 days for patients switched from IV to
PO treatment and 21.0  18.2 days for patients receiving
IV-only treatment (p 0.162).
Actual and hypothetical outcomes based on ES and ED
eligibility
Five hundred and four (33.6%) patients met all of the ES
criteria listed in Table 1 prior to IV discontinuation. Among
these 504 ES-eligible patients, the actual mean (SD) length of
TABLE 2. Patient and disease characteristics
Primary study
population
(N = 1502)
Demographic and clinical characteristics
Age (years), mean  SD 60.9  16.5
Male, n (%) 917 (61.1)
White, n (%) 1395 (92.9)
Charlson Comorbidity Index, mean  SD 2.3  2.2
Infection characteristics
Primary reason for hospitalization is
treatment of MRSA cSSTI, n (%)
1214 (80.8)
Timing of cSSTI index diagnosis, n (%)
At hospital admission 1246 (83.0)
1–3 days after admission 48 (3.2)
≥4 days after admission 208 (13.8)
Type of cSSTI, n (%)
Surgical site infection or
post-traumatic wound
390 (26.0)
Major abscess 265 (17.6)
Infected ulcer 371 (24.7)
Deep/extensive cellulitis 392 (26.1)
Other (including infected burn) 84 (5.6)
cSSTI location, n (%)
Head/skull/neck 62 (4.1)
Torso/abdomen 456 (30.4)
Upper extremity 224 (14.9)
Lower extremity 760 (50.6)
Sepsis, defined as severe sepsis or septic
shock during cSSTI episode, n (%)
258 (17.2)
Procedures and treatments
Surgical procedures for cSSTI
treatment, n (%)
582 (38.7)
Total number of procedures, mean  SD 0.4  0.6
Patient switched from IV to PO inpatient MRSA-active
treatment, n (%)
161 (10.7)
Patient received MRSA-targeted treatment at discharge,
n (%)
483 (32.2)
cSSTI, complicated skin and soft tissue infection; IV, intravenious; MRSA,
methicillin-resistant Staphylococcus aureus; PO, oral; SD, standard deviation.
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IV treatment was 15.4  9.2 days, but hypothetically could
have been 9.4  7.7 days if days after all ES criteria had been
met were removed, suggesting a potential reduction in IV
treatment duration of 6.0  5.5 days (Fig. 1).
A total of 569 (37.9%) patients met all of the ED criteria
listed in Table 1 prior to hospital discharge. The actual and
hypothetical mean LOS for these 569 ED-eligible patients were
20.8  14.8 and 14.6  11.9 days, respectively, suggesting a
potential reduction in LOS of 6.2  8.2 days (Fig. 1).
On the assumption of an average cost of €345 per bed-day
(Appendix S1), the total savings for the randomly selected
population would be over €1.2 million, with more than
€2000 in bed-day cost savings being realized per ED-eligible
patient.
TABLE 3. Targeted methicillin-resistant Staphylococcus aureus (MRSA) antibiotic selection by line of treatment during
hospitalization and at dischargea
First MRSA-active
antibiotic
(N = 1468)
Last inpatient
MRSA-active antibiotic
(N = 1468)
Discharge MRSA-active
antibiotic
(N = 480)
n %a n % n %
Vancomycin 737 50.2 609 41.5 11 2.3
Linezolid 222 15.1 310 21.1 202 42.1
Clindamycin 159 10.8 141 9.6 95 19.8
Teicoplanin 153 10.4 158 10.8 14 2.9
Ciprofloxacin 101 6.9 105 7.2 58 12.1
Daptomycin 87 5.9 98 6.7 1 0.2
Rifampicin 62 4.2 60 4.1 34 7.1
Tigecycline 48 3.3 54 3.7 2 0.4
TMP-SMX 45 3.1 56 3.8 57 11.9
Fusidic acid 21 1.4 26 1.8 16 3.3
Doxycycline 14 1.0 25 1.7 21 4.4
TMP-SMX, trimethoprim–sulfamethoxazole.
aData presented for the subgroup of patients in the random MRSA-active treatment cohort. Because the listed medications may have been used together and these categories are
not mutually exclusive, the sum of percentages is >100%.
ES-eligible
patients
33.6%
Actual
15.4
Hypothetical
9.4
Actual
20.8
Hypothetical
14.6
Potential to save 6.0 
IV days on average 
owing to ES eligibility
Potential to save 6.2 
bed-days on average 
owing to ED eligibility
IV days saved in ES-eligible patients
(n = 504)
Bed-days saved in ED-eligible patients
(n = 569)
ED-eligible
patients
37.9%
20
25
15
10
5
0
FIG 1. Comparison of actual and
hypothetical intravenous (IV) days and
bed-days in early switch (ES)-eligible and
early discharge (ED)-eligible patients.
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Discussion
This is the first pan-European study evaluating actual real-
world clinical practice and ES and ED opportunities in
hospitalized patients with MRSA cSSTI. More than one-third
of patients met ES (33.6%) or ED (37.9%) criteria. Wide
variability in ES and ED eligibility was found across countries,
which may reflect local policies or guidelines. A potential
6.2-day reduction in LOS (~€2000 reduction in bed-day costs)
per ED-eligible patient suggests missed opportunities, because
the observed reduction was only 2 days for IV-to-PO switch
patients. More consistent use of a criteria-based ES and ED
protocol could further shorten LOS by 4 bed-days for eligible
patients.
A growing demand exists for real-world comparative
effectiveness data in many countries, as clinical trial popula-
tions are often not reflective of a typical patient population
seen in clinical practice. Our study provides a snapshot of
treatment patterns by using consistent methodology across 12
countries, making this analysis unique, as few databases in
Europe have both clinical and resource utilization details.
The low frequency of use of co-trimoxazole was surprising
in this real-world study; however, it is possible that initial
treatment with IV co-trimoxazole is less likely to be used when
patients are first admitted, are more unstable, and microbio-
logical diagnosis is less certain. Evidence to support the use of
co-trimoxazole in cSSTI is old and weak, with no clinical trials
for this indication. Furthermore, oral co-trimoxazole is
recommended for community-acquired MRSA in ambulatory
settings [14]. Once patients have stabilized and microbiology
has confirmed susceptibility, its use for PO switch is more
likely to occur, which was reflected by its greater use as a
discharge antibiotic in our study.
Our study results are similar to those of published studies
enrolling patients with various infectious diseases in several
European countries and the USA, which suggest that ~30% to
>50% of patients could be switched from IV to PO treatment
[7,10,15–18] and that 20–30% of patients could be discharged
home sooner when on PO antibiotics [7,10,17]. Most of these
studies were conducted in one institution [7,10,16,18] and
enrolled patients with various infections; some studies pro-
vided aggregated economic projections based on single
countries [7,19].
Our study is unique, as the patient population is large and
captures real-world practice data and potential opportunities
across Europe specifically for MRSA cSSTI. Approximately 17%
of our study population had sepsis, which was a higher
proportion than observed in a randomized study that
compared linezolid and vancomycin for MRSA cSSTI [20],
suggesting that potential ES/ED opportunities may be even
greater in patients with non-MRSA-confirmed cSSTI.
As this study was a retrospective medical chart review,
some study design limitations are inherent. Information was
dependent on or was estimated on the basis of medical
records (e.g. dates on which patients met the criteria for ES/
ED). When prescribed medications were not indicated for
MRSA but were potentially MRSA-active, susceptibility infor-
mation was only available if documented in medical charts. As
this was a retrospective study, not all ES/ED criteria could be
applied at inclusion to determine actual (rather than potential)
cost savings. For this reason, patients switched from IV to PO
antibiotics were compared with those receiving IV-only
treatment. The results could be influenced by a disease
severity bias in those receiving IV-to-PO switch treatment vs.
IV-only treatment; the latter’s potentially less severe disease
and better health status may result in a shorter LOS. Although
IV-only treatment was associated with significantly higher rates
of diabetes and cerebrovascular disease than switch from IV to
PO treatment, the incidence of sepsis was similar between
treatment groups.
Patients hospitalized with cSSTI were selected according to
prespecified definitions. Furthermore, the study design masked
the identities of the study sponsor from recruited physicians.
The investigators created a design and robust application of ES/
ED criteria with a systematic approach that was effective
elsewhere [17]. The applicability of the ES/ED criteria in this
study needs to be validated prospectively. However, aware-
ness of prospective evaluation of ES/ED criteria might influence
the participating centres, potentially jeopardizing the results.
The medical literature identifies several cost drivers for the
treatment of serious multidrug resistant bacteria that are
dependent on the type and severity of the infections (e.g. for
cSSTI: drug acquisition costs; hospital LOS; need for patient
isolation; and development of complications, such as abscess
or the requirement for surgery) [21,22]. Increased LOS is the
key cost driver [23]. Identification of ES/ED opportunities for
patients with MRSA cSSTI hospitalized in Europe could lead to
significant reductions in LOS, thereby providing a mechanism
for improving throughput and increasing efficiency. This
cost-efficiency strategy is recognized as an approach whereby
more patients can receive healthcare with the same invest-
ment in fixed costs [24]. ES/ED will not only provide resource
advantages, but will also underpin the premise of safe, effective
and high-quality, patient-centred care—a core European
healthcare delivery strategy (http://www.euro.who.int/__data/
assets/pdf_file/0007/98233/E91397.pdf). These data could pro-
vide the stimulus for the development of effective implemen-
tation strategies (e.g. care pathways) for managing cSSTI within
European hospitals and the outpatient setting [25].
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Conclusions
Our data suggest that a substantial number of patients with
MRSA cSSTI could be switched to PO therapy and discharged
earlier from hospital, resulting in cost savings across European
healthcare systems. The development and implementation of a
pragmatic care pathway for patients with MRSA cSSTI enabling
early identification, ES and, ultimately, ED of patients safely
treatable for MRSA cSSTI is warranted.
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